Literature DB >> 3040200

Effects of aluminum(III), chromium(III), and iron(III) on the rate of dissolution of calcium hydroxyapatite crystals in the absence and presence of the chelating agent desferrioxamine.

M R Christoffersen, H C Thyregod, J Christoffersen.   

Abstract

Aluminum ions (Al) and chromium (III) ions (Cr), as they exist in aqueous solution at neutral pH, adsorb onto calcium hydroxyapatite crystals (HAP) and severely inhibit their dissolution process, when present in concentrations less than 1 microM. Iron (III) ions (Fe), at concentrations up to 10 microM, have no effect on the dissolution process of HAP. The Fe-chelating agent desferrioxamine also forms strong complexes with Al but not with Cr. Desferrioxamine prevents the adsorption of Al to HAP and removes pre-adsorbed Al from the HAP surface, although not instantaneously, but has no significant effect on the adsorption of Cr to HAP. Desferrioxamine is also found to be capable of removing Al preadsorbed to bone powder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040200     DOI: 10.1007/BF02555127

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Desferrioxamine and osteomalacia.

Authors:  A H Mudde; A P Roodvoets
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

2.  Ultrastructural localization of aluminum in patients with dialysis-associated osteomalacia.

Authors:  A H Verbueken; F L Van de Vyver; R E Van Grieken; G J Paulus; W J Visser; P D'Haese; M E De Broe
Journal:  Clin Chem       Date:  1984-05       Impact factor: 8.327

Review 3.  Action of trace elements in the mineralisation of hard tissues.

Authors:  J A Weatherell; C Robinson
Journal:  Proc Finn Dent Soc       Date:  1982

4.  The effect of aluminum on the rate of dissolution of calcium hydroxyapatite--a contribution to the understanding of aluminum-induced bone diseases.

Authors:  M R Christoffersen; J Christoffersen
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

5.  Treatment of dialysis osteomalacia with desferrioxamine.

Authors:  D J Brown; J K Dawborn; K N Ham; J M Xipell
Journal:  Lancet       Date:  1982-08-14       Impact factor: 79.321

6.  The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure.

Authors:  H H Malluche; A J Smith; K Abreo; M C Faugere
Journal:  N Engl J Med       Date:  1984-07-19       Impact factor: 91.245

7.  Quantitation and localisation of aluminum in human cancellous bone in renal osteodystrophy.

Authors:  B F Boyce; H Y Eider; S G Fell; W A Nicholson; G D Smith; D W Dempster; C C Gray; I T Boyle
Journal:  Scan Electron Microsc       Date:  1981

8.  Histological quantitation of aluminum in iliac bone from patients with renal failure.

Authors:  N A Maloney; S M Ott; A C Alfrey; N L Miller; J W Coburn; D J Sherrard
Journal:  J Lab Clin Med       Date:  1982-02
  8 in total
  2 in total

1.  Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease.

Authors:  T Diamond; R Pojer; D Stiel; A Alfrey; S Posen
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

2.  Magnetic calcium phosphates nanocomposites for the intracellular hyperthermia of cancers of bone and brain.

Authors:  Alessio Adamiano; Victoria M Wu; Francesca Carella; Gianrico Lamura; Fabio Canepa; Anna Tampieri; Michele Iafisco; Vuk Uskoković
Journal:  Nanomedicine (Lond)       Date:  2019-05       Impact factor: 5.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.